Next Article in Journal
Chemical Synthesis, Pharmacokinetic Properties and Biological Effects of JM-00266, a Putative Non-Brain Penetrant Cannabinoid Receptor 1 Inverse Agonist
Next Article in Special Issue
Genetic Landscape of Chronic Myeloid Leukemia and a Novel Targeted Drug for Overcoming Resistance
Previous Article in Journal
Genome-Wide Identification, Characterization, and Expression Profiling of AP2/ERF Superfamily Genes under Different Development and Abiotic Stress Conditions in Pecan (Carya illinoinensis)
Previous Article in Special Issue
Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia
 
 

Order Article Reprints

Journal: Int. J. Mol. Sci., 2022
Volume: 23
Number: 2919

Article: The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma
Authors: by Reiko Isa, Mano Horinaka, Taku Tsukamoto, Kentaro Mizuhara, Yuto Fujibayashi, Yoko Taminishi-Katsuragawa, Haruya Okamoto, Shusuke Yasuda, Yuka Kawaji-Kanayama, Yayoi Matsumura-Kimoto, Shinsuke Mizutani, Yuji Shimura, Masafumi Taniwaki, Toshiyuki Sakai and Junya Kuroda
Link: https://www.mdpi.com/1422-0067/23/6/2919

MDPI provides article reprints in high quality with convenient shipping to destinations worldwide. The articles are printed in on premium paper with high-resolution figures. Our covers are customized to your article and designed to be complimentary to the journal. These reprints are ideal additions to your portfolio. Copy details: 135g/m2 paper, 2x stitched, full colour and glossy finish, orderable in quantities from 10 to 1000.

If you have any questions, or special requests, please write to our support team; we are happy to provide you with the information you need.

Reprint Options

If you need more than 400 copies, please contact us by e-mail (publisher@mdpi.com) and we will prepare an individual offer for you.

Order Cost and Details

Contact Person

Invoice Address

Notes or Comments

Validate and Place Order

The order must be prepaid after it is placed

req denotes required fields.
Back to TopTop